{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:49:51Z","timestamp":1791859791507,"version":"4.3.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Global 12-month psychosis prevalence is estimated at roughly 0.4%, although prevalence of antipsychotic use in the U.S. is estimated at roughly 1.7%. Antipsychotics are frequently prescribed for off label uses, but have also been shown to carry risk factors for certain comorbid conditions and with other prescription medications. The study aims to describe the socio-demographic and health characteristics of U.S. adults taking prescription antipsychotic medications, and to better understand the association of antipsychotic medications and comorbid chronic diseases.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>The study pools 2013\u20132018 data from the National Health and Nutrition Examination Survey (NHANES), a nationally representative cross-sectional survey of non-institutionalized U.S. residents (<jats:italic>n<\/jats:italic>\u2009=\u200917,691). Survey staff record prescription medications taken within the past 30\u2009days for each respondent, from which typical and atypical antipsychotic medications were identified.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Prevalence of antipsychotic use among U.S. adults was 1.6% (<jats:italic>n<\/jats:italic>\u2009=\u2009320). Over 90% of individuals taking antipsychotics reported having health insurance and a usual place for care, significantly more than their counterparts not taking antipsychotics. Further, those taking antipsychotics reported higher prevalence of comorbid chronic diseases and took an average of 2.3 prescription medications more than individuals not taking antipsychotics. Individuals taking antipsychotics were more likely to sleep 9 or more hours per night, be a current smoker, and have a body mass index greater than 30\u2009kg\/m<jats:sup>2<\/jats:sup>.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>U.S. adults who take antipsychotic medications report more consistent health care access and higher prevalence of comorbid chronic diseases compared to those not taking antipsychotics. The higher comorbidity prevalence and number of total prescriptions highlight the need for careful assessment and monitoring of existing comorbidities and potential drug-drug interactions among adults taking antipsychotics in the U.S.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12888-020-02895-4","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T09:03:58Z","timestamp":1601543038000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Characteristics of U.S. adults taking prescription antipsychotic medications, National Health and Nutrition Examination Survey 2013\u20132018"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0264-3635","authenticated-orcid":false,"given":"Jeff A.","family":"Dennis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisaann S.","family":"Gittner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Drew","family":"Payne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Nugent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,1]]},"reference":[{"key":"2895_CR1","unstructured":"Schizophrenia. [Internet] May 2018. Cited May 16, 2020. Available from: https:\/\/www.nimh.nih.gov\/health\/statistics\/schizophrenia.shtml."},{"issue":"4","key":"2895_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0195687","volume":"13","author":"B Moreno-K\u00fcstner","year":"2018","unstructured":"Moreno-K\u00fcstner B, Martin C, Pastor L. Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses. PloS One. 2018;13(4):1\u201325.","journal-title":"PloS One"},{"issue":"1","key":"2895_CR3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3122\/jabfm.2011.01.100121","volume":"24","author":"RS Shim","year":"2011","unstructured":"Shim RS, Baltrus P, Ye J, Rust G. Prevalence, treatment, and control of depressive symptoms in the United States: results from the National Health and nutrition examination survey (NHANES), 2005\u20132008. J Am Board Fam Med. 2011;24(1):33\u20138.","journal-title":"J Am Board Fam Med"},{"key":"2895_CR4","unstructured":"Goodell S, Druss BG, Walker ER, Mat M. Mental disorders and medical comorbidity. Robert Wood Johnson Foundation 2011;2."},{"issue":"1","key":"2895_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/JCP.0000000000000924","volume":"39","author":"J de Leon","year":"2019","unstructured":"de Leon J. Why do you keep telling me that drug-drug interactions are important in psychopharmacology when I do not see them in my clinical practice?: my failure to convince clinicians. J Clin Psychopharmacol. 2019;39(1):1\u20134.","journal-title":"J Clin Psychopharmacol"},{"issue":"10","key":"2895_CR6","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1080\/14740338.2016.1201475","volume":"15","author":"L Orsolini","year":"2016","unstructured":"Orsolini L, Tomasetti C, Valchera A, Vecchiotti R, Matarazzo I, Vellante F, Iasevoli F, Buonaguro EF, Fornaro M, Fiengo AL, Martinotti G. An update of safety of clinically used atypical antipsychotics. Expert Opin Drug Saf. 2016;15(10):1329\u201347.","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"2895_CR7","first-page":"617","volume":"81","author":"J Muench","year":"2010","unstructured":"Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician. 2010;81(5):617\u201322.","journal-title":"Am Fam Physician"},{"issue":"11","key":"2895_CR8","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1176\/appi.ps.201100443","volume":"63","author":"JJ Guo","year":"2012","unstructured":"Guo JJ, Wu J, Kelton CM, Jing Y, Fan H, Keck PE, Patel NC. Exposure to potentially dangerous drug-drug interactions involving antipsychotics. Psychiatr Serv. 2012;63(11):1080\u20138.","journal-title":"Psychiatr Serv"},{"key":"2895_CR9","unstructured":"Maglione M, Maher AR, Hu J, Wang Z, Shanman R, Shekelle PG, Roth B, Hilton L, Suttorp MJ, Ewing BA, Motala A. Off-label use of atypical antipsychotics: an update. InDatabase of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] 2011. Centre for Reviews and Dissemination (UK)."},{"issue":"12","key":"2895_CR10","first-page":"32","volume":"5","author":"F Tremeau","year":"2006","unstructured":"Tremeau F, Citrome L. Antipsychotics for patients without psychosis? What clinical trials support. Curr Psychiatry. 2006;5(12):32.","journal-title":"Curr Psychiatry"},{"issue":"12","key":"2895_CR11","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1001\/archgenpsychiatry.2012.647","volume":"69","author":"M Olfson","year":"2012","unstructured":"Olfson M, Blanco C, Liu SM, Wang S, Correll CU. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry. 2012;69(12):1247\u201356.","journal-title":"Arch Gen Psychiatry"},{"key":"2895_CR12","unstructured":"enters for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2013-2018. http:\/\/www.cdc.gov\/nchs\/nhanes.htm. Accessed 15 May 2020."},{"key":"2895_CR13","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.schres.2020.03.048","volume":"220","author":"J Reutfors","year":"2020","unstructured":"Reutfors J, Cesta CE, Cohen JM, Bateman BT, Brauer R, Einarsd\u00f3ttir K, Engeland A, Furu K, Gissler M, Havard A, Hernandez-Diaz S. Antipsychotic drug use in pregnancy: A multinational study from ten countries. Schizophr Res. 2020;220:106\u201315.","journal-title":"Schizophr Res"},{"issue":"23","key":"2895_CR14","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.2174\/1381612821666150619092903","volume":"21","author":"L Carton","year":"2015","unstructured":"Carton L, Cottencin O, Lapeyre-Mestre MA, Geoffroy P, Favre J, Simon N, Rolland B. Off-label prescribing of antipsychotics in adults, children and elderly individuals: a systematic review of recent prescription trends. Curr Pharm Des. 2015;21(23):3280\u201397.","journal-title":"Curr Pharm Des"},{"issue":"8","key":"2895_CR15","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1176\/appi.ps.201500316","volume":"67","author":"J Driessen","year":"2016","unstructured":"Driessen J, Baik SH, Zhang Y. Trends in off-label use of second-generation antipsychotics in the Medicare population from 2006 to 2012. Psychiatr Serv. 2016;67(8):898\u2013903.","journal-title":"Psychiatr Serv"},{"issue":"5","key":"2895_CR16","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1176\/ps.2010.61.5.469","volume":"61","author":"S Ryan","year":"2010","unstructured":"Ryan S, Brown CK, Watanabe-Galloway S. Toward successful postbooking diversion: what are the next steps? Psychiatr Serv. 2010;61(5):469\u201377.","journal-title":"Psychiatr Serv"},{"key":"2895_CR17","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1001\/jama.2017.7032","volume":"318","author":"JH Gurwitz","year":"2017","unstructured":"Gurwitz JH, Bonner A, Berwick DM. Reducing excessive use of antipsychotic agents in nursing homes. JAMA. 2017;318:118\u20139.","journal-title":"JAMA"},{"key":"2895_CR18","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1108\/S1057-629020160000017010","volume-title":"50 years after deinstitutionalization: Mental illness in contemporary communities 2016 Bingley","author":"AR Hatch","year":"2016","unstructured":"Hatch AR, Xavier-Brier M, Attell B, Viscarra E. Soldier, elder, prisoner, ward: Psychotropics in the era of transinstitutionalization. In: Perry BL, editor. 50 years after deinstitutionalization: Mental illness in contemporary communities 2016 Bingley. West Yorkshire, England: Emerald Group Publishing Limited; 2016. p. 291\u2013317."},{"issue":"2","key":"2895_CR19","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1176\/appi.ajp.162.2.370","volume":"162","author":"DP Folsom","year":"2005","unstructured":"Folsom DP, Hawthorne W, Lindamer L, Gilmer T, bailey a GS, Garcia P, Un\u00fctzer J, Hough R, Jeste DV. Prevalence and risk factors for homelessness and utilization of mental health services among 10,340 patients with serious mental illness in a large public mental health system. Am J Psych. 2005;162(2):370\u20136.","journal-title":"Am J Psych"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-020-02895-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-020-02895-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-020-02895-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T01:30:54Z","timestamp":1633051854000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-020-02895-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2895"],"URL":"https:\/\/doi.org\/10.1186\/s12888-020-02895-4","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,1]]},"assertion":[{"value":"17 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study used publicly available, de-identified data and did not require review by the Texas Tech University Health Sciences Center Institutional Review Board.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"483"}}